ArticleJournal of fluorescence2025
Establishment of a YKL-40 time-resolved Immunoassay and Application in Diabetic Kidney Disease.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To develop a highly sensitive, wide-linear-range time-resolved fluorescence immunoassay (TRFIA) to detect serum YKL-40 and to measure its concentrations in patients with diabetic kidney disease (DKD). A double-antibody sandwich method was employed to establish the YKL-40 TRFIA, which utilizes two antibodies targeting distinct epitopes on the YKL-40 antigen (a coating antibody and a labeled antibody). The assay's linearity, sensitivity, accuracy, specificity, and recovery rate were evaluated. Serum YKL-40 concentrations were measured in healthy individuals and patients with DKD using this TRFIA. The YKL-40 TRFIA exhibited a linear range of 0.5-2000 ng/mL. Intra-assay and inter-assay coefficients of variation were 3.54-9.71% and 4.79-11.27%, respectively. The recovery rate was 101.73-102.62%. The assay showed no cross-reactivity with YKL-39, galectin-3 or CXCL9 and no serum interference. The YKL-40 TRFIA results were highly consistent with those of ELISA (P < 0.0001). The serum YKL-40 level in DKD patients was 314.78 (184.12, 482.49) ng/mL, significantly higher than that in healthy controls [65.73 (48.71, 98.70) ng/mL; P < 0.001]. This study successfully developed a highly sensitive and wide-linear-range method for YKL-40 detection, which can be used for clinical detection.
Indexed as
Identifiers
40824361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.